Analyst Reco. Syndax Pharmaceuticals, Inc.

Equities

SNDX

US87164F1057

Real-time Estimate Cboe BZX Other stock markets 02:18:35 2024-04-29 pm EDT			5-day change	1st Jan Change
21.08 ^USD	+0.07%		+1.07%	-1.97%

Apr. 08	Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	CI
Mar. 28	Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Raises Price Target on Syndax Pharmaceuticals to $34 From $31, Maintains Overweight Rating	Mar. 20	MT
Scotiabank Downgrades Syndax Pharmaceuticals to Sector Perform From Sector Outperform, Cuts Price Target to $23 From $36	Jan. 31	MT
JPMorgan Adjusts Syndax Pharmaceuticals Price Target to $37 From $38, Maintains Overweight Rating	Nov. 24	MT
BofA Securities Starts Syndax Pharmaceuticals at Buy With $29 Price Target	23-10-25	MT
Scotiabank Cuts Syndax Pharmaceuticals Price Target to $36 From $39, Maintains Sector Outperform Rating	23-10-03	MT
HC Wainwright Adjusts Syndax Pharmaceuticals Price Target to $42 From $38, Maintains Buy Rating	23-10-02	MT
JPMorgan Adjusts Price Target on Syndax Pharmaceuticals to $33 From $36, Keeps Overweight Rating	23-08-16	MT
Scotiabank Starts Syndax Pharmaceuticals at Sector Perform With $39 Price Target	23-07-27	MT
Barclays Adjusts Price Target on Syndax Pharmaceuticals to $34 From $31, Maintains Overweight Rating	23-07-26	MT
B. Riley Raises Syndax Pharmaceuticals' Price Target to $36 From $34 on Heels of Clinical Update for cGVHD, Keeps Buy Rating	23-07-25	MT
Guggenheim Adjusts Price Target on Syndax Pharmaceuticals to $42 From $40, Maintains Buy Rating	23-07-24	MT
Stifel Adjusts Price Target on Syndax Pharmaceuticals to $38 From $37, Maintains Buy Rating	23-07-24	MT
JPMorgan Adjusts Price Target on Syndax Pharmaceuticals to $36 From $32, Maintains Overweight Rating	23-07-24	MT
HC Wainwright Adjusts Syndax Pharmaceuticals' Price Target to $38 From $36, Keeps Buy Rating	23-07-24	MT
Guggenheim Initiates Syndax Pharmaceuticals With Buy Rating, $40 Price Target	23-07-11	MT
BTIG Adjusts Price Target on Syndax Pharmaceuticals to $35 From $34, Keeps Buy Rating	23-06-26	MT
Citigroup Adjusts Price Target on Syndax Pharmaceuticals to $31 From $32, Keeps Buy Rating	23-05-10	MT
HC Wainwright Adjusts Syndax Pharmaceuticals' Price Target to $36 From $33, Keeps Buy Rating	23-05-09	MT
JPMorgan Adjusts Price Target on Syndax Pharmaceuticals to $36 From $41, Maintains Overweight Rating	23-03-07	MT
Citigroup Adjusts Price Target on Syndax Pharmaceuticals to $32 From $29, Maintains Buy Rating	23-03-02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Syndax Pharmaceuticals, Inc.

Equities

SNDX

US87164F1057

Analyst Reco.

Filters